ArticleHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2018

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Nazzareno Cervelli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.